Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI response’s central claim about serious sequelae from abrupt withdrawal of intrathecal baclofen and the labeled prevention measures (programming/monitoring, refill scheduling/procedures, pump alarms/early symptom education) is directly supported by the provided FDA label excerpts (Section 5, with additional discontinuation guidance from Section 2).
Category Scores
Accurate Statements
Abrupt withdrawal/discontinuation of intrathecal baclofen can cause serious sequelae including high fever, altered mental status, exaggerated rebound spasticity, and muscle rigidity.
Supported by SECTION 5 — WARNINGS (states abrupt withdrawal/discontinuation has resulted in sequelae including high fever, altered mental status, exaggerated rebound spasticity and muscle rigidity).
Abrupt withdrawal/discontinuation of intrathecal baclofen can include rare progression to rhabdomyolysis, multiple organ-system failure, and death.
Supported by SECTION 5 — WARNINGS (rare progression to rhabdomyolysis, multiple organ-system failure, and death).
Prevention requires careful pump programming/monitoring.
Supported by SECTION 5 — WARNINGS (prevention requires careful attention to programming and monitoring of the infusion system).
Prevention requires refill scheduling/procedures and attention to pump alarms.
Supported by SECTION 5 — WARNINGS (prevention requires refill scheduling and procedures, and pump alarms).
Except in overdose related emergencies, the dose should ordinarily be reduced slowly if the drug is discontinued (and abrupt reduction/discontinuation of concomitant antispasticity medications should be avoided).
Supported by SECTION 2 — DOSAGE AND ADMINISTRATION (dose reduction slowly if discontinued; avoid abrupt reduction/discontinuation of concomitant antispastics).
Unsupported Statements
Contradictions
Important Omissions
The claim does not mention that symptoms may appear within hours to a few days following interruption, nor the listed common reasons for abrupt interruption (e.g., catheter disconnection, low pump reservoir volume, end of battery life, and intrathecal mass at catheter tip).
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The evaluated response is consistent with labeled safety warnings and prevention measures; it does not introduce conflicting or unsafe instructions relative to the provided FDA label excerpts.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Minor omission of additional labeled details (timing and common causes of interruption) that were not required to support the core claim.
Suggested Improvement
If expanding the statement, include the label’s additional timing and common causes of abrupt interruption, and/or mention patient/caregiver education on early withdrawal symptoms as explicitly stated in Section 5.